It is of note, however, that we could not analyze troponins, B‐type natriuretic peptide (BNP), or global systolic longitudinal strain (GLS) which have been found to be predictive of the occurrence and severity of LVEF‐D due to other cancer therapies.20, 21, 22, 23, 24, 25, 26, 27, 28 These parameters are not routinely measured in patients treated with BRAF and MEKis and therefore prospective studies may be conducted in the future to determine whether these parameters could predict cardiac dysfunction in the context of therapeutic BRAF and MEK inhibition. The gene discussed is NPPB; the disease is cancer.